Project

Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreat-ed, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Ongoing - recruitment closed · 2020 until 2029

Früh Martin